HomeM1RN34 • BVMF
add
Moderna Inc Bdr
Previous close
R$34.29
Day range
R$32.88 - R$34.19
Year range
R$16.70 - R$44.00
Market cap
47.54B USD
Avg Volume
21.98K
Top news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 167.00M | -91.03% |
Operating expense | 274.00M | -10.16% |
Net income | -1.18B | -1,587.34% |
Net profit margin | -703.59 | -16,694.10% |
Earnings per share | -3.07 | -1,715.79% |
EBITDA | -1.23B | -327.08% |
Effective tax rate | -0.86% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 8.52B | -4.48% |
Total assets | 16.73B | -30.66% |
Total liabilities | 3.91B | -25.66% |
Total equity | 12.82B | — |
Shares outstanding | 383.24M | — |
Price to book | 1.02 | — |
Return on assets | -18.01% | — |
Return on capital | -21.71% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -1.18B | -1,587.34% |
Cash from operations | -989.00M | 19.27% |
Cash from investing | 118.00M | -94.13% |
Cash from financing | 14.00M | 102.58% |
Net change in cash | -857.00M | -451.23% |
Free cash flow | -845.00M | 33.64% |
About
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. Wikipedia
Founded
Sep 2010
Website
Employees
5,600